Ysios Capital — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)Nadim Yared(Executive Officer, Director)Dean Bruhn-Ding(Executive Officer)John Brintnall(Executive Officer)Liz Galle(Executive Officer)
BoardGeoff Pardo(Director)
Co-investorsNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersHatteras Venture PartnersVensana Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.